socalTECH
SEPTEMBER 20, 2010
In a blog post , Brisco said that the firm decided to become a private firm again, because it would be a "good deal" for shareholders, and also said it could become "even more focused" on long-term growth. Internet Brands had gone public just three years ago.
Xconomy
SEPTEMBER 30, 2016
—Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
AUGUST 26, 2016
—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease.
Xconomy
JULY 22, 2016
—Bruce Bigelow profiled Dauntless Pharmaceuticals , a stealthy biotech company creator in San Diego forming single-drug startups. —San Francisco gene therapy startup Audentes Pharmaceuticals (NASDAQ: BOLD ) raised $75 million in an IPO , selling 5 million shares at $15 apiece, right in its projected range.
Xconomy
AUGUST 5, 2016
—Meanwhile, scientists from San Diego-based Synthetic Genomics and the J. Adicet raised $51 million earlier this year… Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, is paying $40 million immediately for rights to ADXS-NEO , a preclinical cancer treatment from Princeton, NJ-based Advaxis (NASDAQ: ADXS ).
Xconomy
JUNE 10, 2016
—On the positive side, Thousand Oaks, CA-based Amgen (NASDAQ: AMGN ) released an overview of Phase 2 data that showed its migraine prevention drug, erenumab, is keeping pace with rival drugs in a heated race to market.
Expert insights. Personalized for you.
190 
Let's personalize your content